Trials / Completed
CompletedNCT03620890
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy: a Comparative-effectiveness, Open Label, Randomized Controlled Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 108 (actual)
- Sponsor
- The University of Texas Health Science Center, Houston · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine whether use of detemir compared to neutral protamine hagedorn (NPH) decreases rates of composite neonatal outcome and maternal hypoglycemia events in women with Type 2 Diabetes Mellitus (T2DM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Neutral Protamine Hagedorn (NPH) | NPH will peak between 4-12 hours after injection with a duration of action around 14 hours |
| DRUG | Detemir insulin | Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours) |
Timeline
- Start date
- 2018-09-04
- Primary completion
- 2020-07-29
- Completion
- 2020-07-29
- First posted
- 2018-08-08
- Last updated
- 2021-09-16
- Results posted
- 2021-08-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03620890. Inclusion in this directory is not an endorsement.